Sign inJoin waitlistJoin the waitlist

Haider Mahdi

Physician · Salem Health Hospitals and Clinics

Credentials: · · · · · ·

History

Salem Health Hospitals and Clinics
2026–Present

Diagnostic Radiology
Henry Ford Hospital
2021–2022
University of Washington School of Medicine
2015–2019
Gynecologic Oncology
Cleveland Clinic Foundation
2012–2015
Wayne State University/Detroit Medical Center
2004–2007
University of Kufa College of Medicine
2000–2004

Research

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 587 citations
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Journal of the National Comprehensive Cancer Network · 2019 · 213 citations
Low-grade serous ovarian cancer: State of the science
Review · Gynecologic Oncology · 2020 · 99 citations

Peter Rose
29 papers
Adnan Munkarah
18 papers
Chad Michener
13 papers
Rouba Ali-Fehmi
12 papers
Mehdi Kebria
11 papers
Robert Edwards
11 papers
AO
Alexander Olawaiye
10 papers
Sanjeev Kumar
10 papers
ST
Sarah Taylor
10 papers
Madeleine Courtney-Brooks
9 papers
Paniti Sukumvanich
9 papers
JL
Jamie Lesnock
8 papers

Grants

HCC Ovarian Cancer SPORE
National Cancer Institute · P50
Project lead · $1.6M · University of Pittsburgh at Pittsburgh
2023–2028

Clinical trials

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
Principal investigator · Withdrawn · Phase 2
Haider Mahdi
2024–2028
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
Principal investigator · Withdrawn · Phase 1
National Cancer Institute (NCI)
2024–2026
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Principal investigator · Withdrawn · Phase 1
Haider Mahdi
2024–2029